EP
CARM

Eversept Partners’s Carisma Therapeutics CARM Stock Holding History

Eversept Partners’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-77,991
Closed -$2.11M – 92
2020
Q4 		$2.11M Hold
77,991
– – 0.25% 42
2020
Q3 		$2.18M Sell
77,991
-22,009
-22% -$440K 0.49% 36
2020
Q2 		$1.44M Buy
100,000
+35,000
+54% +$472K 0.2% 56
2020
Q1 		$729K Hold
65,000
– – 0.18% 50
2019
Q4 		$1.35M Buy
+65,000
New +$1.49M 0.24% 58

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners's CARM Position: Q1 2021 in Review

Eversept Partners sold out of Carisma Therapeutics (CARM) in Q1 2021, closing a stake of 77,991 shares — an estimated $2.11M sold.

Eversept Partners first reported a position in CARM in Q4 2019 and held it in 5 quarters. The position peaked at $2.18M in Q3 2020. 76 funds tracked by Wall St. Rank hold CARM as of Q1 2021.

  • Eversept Partners reported no remaining Carisma Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Eversept Partners sold 77,991 Carisma Therapeutics shares in Q1 2021, an estimated $2.11M.
  • Eversept Partners first reported a position in Carisma Therapeutics in Q4 2019 and held it in 5 quarters.
  • Eversept Partners's Carisma Therapeutics position peaked at $2.18M in Q3 2020.
  • 76 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2021.

Based on Eversept Partners's 13F filing for Q1 2021, filed 13 May 2021.